PH12020551638A1 - Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives - Google Patents

Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Info

Publication number
PH12020551638A1
PH12020551638A1 PH12020551638A PH12020551638A PH12020551638A1 PH 12020551638 A1 PH12020551638 A1 PH 12020551638A1 PH 12020551638 A PH12020551638 A PH 12020551638A PH 12020551638 A PH12020551638 A PH 12020551638A PH 12020551638 A1 PH12020551638 A1 PH 12020551638A1
Authority
PH
Philippines
Prior art keywords
pyrazolo
triazine
pyrimidine derivatives
diseases
pharmaceutically active
Prior art date
Application number
PH12020551638A
Other languages
English (en)
Inventor
Kiyean Nam
Jaeseung Kim
Yeejin Jeon
Donghoon Yu
Mooyoung Seo
Dongsik Park
Jan Eickhoff
Gunther Zischinsky
Uwe Koch
Original Assignee
Qurient Co Ltd
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qurient Co Ltd, Lead Discovery Center Gmbh filed Critical Qurient Co Ltd
Publication of PH12020551638A1 publication Critical patent/PH12020551638A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020551638A 2018-04-11 2020-10-05 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives PH12020551638A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656041P 2018-04-11 2018-04-11
PCT/EP2019/059289 WO2019197546A1 (en) 2018-04-11 2019-04-11 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
PH12020551638A1 true PH12020551638A1 (en) 2021-07-26

Family

ID=66334384

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551638A PH12020551638A1 (en) 2018-04-11 2020-10-05 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Country Status (14)

Country Link
US (1) US11858937B2 (https=)
EP (1) EP3774809A1 (https=)
JP (2) JP7406501B2 (https=)
KR (1) KR20200143429A (https=)
CN (1) CN112334471A (https=)
AU (1) AU2019250504B2 (https=)
BR (1) BR112020020645A2 (https=)
CA (1) CA3095426A1 (https=)
IL (2) IL299105B2 (https=)
MX (1) MX2020010563A (https=)
MY (1) MY207194A (https=)
PH (1) PH12020551638A1 (https=)
SG (1) SG11202009466UA (https=)
WO (1) WO2019197546A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20250263413A1 (en) * 2020-12-02 2025-08-21 Qurient Co., Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
US20240343732A1 (en) * 2021-05-28 2024-10-17 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7(cdk7)
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
EP4493193A1 (en) * 2022-03-18 2025-01-22 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
US20260041693A1 (en) 2022-08-05 2026-02-12 Qurient Co., Ltd. Combination therapy of cdk7 inhibitors with other anti-cancer therapies
KR20240095030A (ko) 2022-12-15 2024-06-25 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP2634189A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) * 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Also Published As

Publication number Publication date
IL299105B2 (en) 2024-02-01
MY207194A (en) 2025-02-05
JP7406501B2 (ja) 2023-12-27
US11858937B2 (en) 2024-01-02
AU2019250504B2 (en) 2023-05-18
NZ768400A (en) 2024-07-05
CN112334471A (zh) 2021-02-05
SG11202009466UA (en) 2020-10-29
BR112020020645A2 (pt) 2021-01-12
US20210139483A1 (en) 2021-05-13
EP3774809A1 (en) 2021-02-17
MX2020010563A (es) 2020-10-22
WO2019197546A1 (en) 2019-10-17
IL299105A (en) 2023-02-01
AU2019250504A1 (en) 2020-10-15
JP2023138859A (ja) 2023-10-02
CA3095426A1 (en) 2019-10-17
KR20200143429A (ko) 2020-12-23
IL299105B1 (en) 2023-10-01
IL277694A (en) 2020-11-30
JP2021521129A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2014010494A (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
NZ766835A (en) Pharmaceutical compounds
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EP4072548A4 (en) COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZINE-1-YL)PYRAZOLO[ 1,5-A]PYRIMIDINE ANALOGUES AS INHIBITORS BY KRAS
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MY206712A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
MY192029A (en) 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX2010001677A (es) Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
PH12022550470A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
MX2017007429A (es) Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
ZA202100159B (en) Imidazo[1,2-b]pyridazines as trk inhibitors
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний